logo
Cart is empty
Patient Portal
Cart Patient Portal

Protect yourself with personalised prostate cancer prevention

Detect your genetic prostate cancer risks early and get actionable medical advice for prevention to protect your health.

I'm interested Start today

Provided and supported by

PSA-testing is not enough. Smarter screening starts with knowing your genetic risk.

Next-generation cancer prevention considers your risk profile

Prostate cancer is the most common cancer in men in the United Kingdom and a major cause of cancer-related deaths. Early detection of aggressive, clinically significant cancer can save lives. However, PSA testing alone is not enough – many serious cases may be missed, because PSA levels may remain in the “normal” range.

Personal cancer prevention with genetic risk assessment can give early warning to men at risk even if there is no cancer in the family. It guides you towards tailored screening and prevention based on personal risk level.

Learn more

Who is it for?

  • Recommended for all men aged 40 and above.
  • Perfect for health-conscious men, with or without a family history of cancer, who wish to take control of their health and prevent prostate cancer through early detection.

 

 

Learn more
Personalised prostate cancer prevention for men in the UK

Here’s what you’ll learn:

  • What is your genetic risk level for prostate cancer

  • When should you begin prostate cancer screening, and how often

  • Are there additional measures you can take to lower your risk

  • What proactive measures can you adopt to reduce your likelihood of developing prostate cancer

  • What changes or symptoms should you monitor

  • What should your doctor know

What's new?

This approach enables tailored prevention and earlier action, when it matters most. This approach adds genetic risk assessment to traditional screening, combining:

  • Polygenic Risk Score (PRS) testing to evaluate genetic risk level based on common genetic variants. PRS testing is done once in a lifetime.
  • Family cancer history assessment with recommendations for further testing of high-risk gene mutations (e.g. BRCA2) if needed.
  • A personalised medical prevention plan that takes into account your risk profile and advises when and how often to initiate screening, which methods are most effective for you, and what else you can do to reduce your risk.

 

The service is based on the latest scientific research

  • About 58% of prostate cancer risk is inherited.
  • Men with a high genetic risk have a threefold increase in the risk of early mortality.
  • Standard PSA-based screening may miss these high-risk cases. PSA levels can remain normal even when cancer is already developing.
  • However, timely and thorough diagnostics can help to prevent this.
  • PRS testing can identify high risk, with or without a family history of cancer.
  • For those at high genetic risk, we recommend prostate MRI scans as part of screening, even if their PSA levels are within the normal range.
illustration

Powered by Innovative Polygenic Risk Score (PRS)

PRS is an innovative, non-intrusive method for predicting disease risk to enable personalised prevention. The use of PRS genetic tests in clinical practice represents a modern standard of care in personalised medicine, supported by extensive research data and clinical evidence from numerous studies.

Our PRS calculates the combined effect of 121 genetic variants associated with prostate cancer. By combining the PRS with a person’s background (origin, age, and gender), we are able to calculate a person’s risk of developing cancer. Moreover, we provide tailored medical advice to prevent illness or promote early detection.

Approved by doctors and customers

Over 16 000 valuable insights from us

Developed & supported by leading healthcare professionals

All our services are developed in co-operation with leading oncologists, medical geneticists and bioinformaticians across Europe and the UK.

  • Peeter Padrik, MD, PhD Oncologist
  • Neeme Tõnisson, MD, PhD Medical Geneticist
  • Siim Sõber, PhD Chief Product Officer
RESOURCES

Latest articles and scientific publications

Fully compliant with all regulatory bodies

Personalised cancer prevention is based on genetic risk tests provided by Antegenes.

✔ CE-marked medical devices (in vitro diagnostics, IVD)
✔ Registered in the UK MHRA Registry and EUDAMED database
✔ Developed using anonymised data from the UK Biobank
✔ Antegenes is ISO 13485 certified
✔ We take your data privacy and protection very seriously

Prevent
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.